In its Q1 2026 10-Q filing, Adaptin Bio, Inc. reveals severe liquidity constraints marked by a current ratio of 0.28 and current liabilities outstripping current assets by a wide margin. Despite this, the company continues to leverage intellectual property partnerships with Duke University, including patent licensing and sponsored research agreements, which form the cornerstones of its early-stage biotech business model. The firm’s limited funding runway underscores the critical need for capital raises while operational efforts remain focused on advancing preclinical and discovery-stage programs. Executive employment agreements combined with equity incentive plans aim to mitigate talent retention risks amid these financial limitations.